Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-linear-accelerator: a prospective R-IDEAL stage 0-2a quantitative/qualitative evaluation of

fat suppression head and neck cancer magnetic resonance imaging/linear accelerator

Journal

Journal of medical imaging (Bellingham, Wash.)
ISSN: 2329-4302
Titre abrégé: J Med Imaging (Bellingham)
Pays: United States
ID NLM: 101643461

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 16 05 2023
revised: 06 10 2023
accepted: 16 10 2023
pmc-release: 06 11 2024
medline: 8 11 2023
pubmed: 8 11 2023
entrez: 8 11 2023
Statut: ppublish

Résumé

To improve segmentation accuracy in head and neck cancer (HNC) radiotherapy treatment planning for the 1.5T hybrid magnetic resonance imaging/linear accelerator (MR-Linac), three-dimensional (3D), T2-weighted, fat-suppressed magnetic resonance imaging sequences were developed and optimized. After initial testing, spectral attenuated inversion recovery (SPAIR) was chosen as the fat suppression technique. Five candidate SPAIR sequences and a nonsuppressed, T2-weighted sequence were acquired for five HNC patients using a 1.5T MR-Linac. MR physicists identified persistent artifacts in two of the SPAIR sequences, so the remaining three SPAIR sequences were further analyzed. The gross primary tumor volume, metastatic lymph nodes, parotid glands, and pterygoid muscles were delineated using five segmentors. A robust image quality analysis platform was developed to objectively score the SPAIR sequences on the basis of qualitative and quantitative metrics. Sequences were analyzed for the signal-to-noise ratio and the contrast-to-noise ratio and compared with fat and muscle, conspicuity, pairwise distance metrics, and segmentor assessments. In this analysis, the nonsuppressed sequence was inferior to each of the SPAIR sequences for the primary tumor, lymph nodes, and parotid glands, but it was superior for the pterygoid muscles. The SPAIR sequence that received the highest combined score among the analysis categories was recommended to Unity MR-Linac users for HNC radiotherapy treatment planning. Our study led to two developments: an optimized, 3D, T2-weighted, fat-suppressed sequence that can be disseminated to Unity MR-Linac users and a robust image quality analysis pathway that can be used to objectively score SPAIR sequences and can be customized and generalized to any image quality optimization protocol. Improved segmentation accuracy with the proposed SPAIR sequence will potentially lead to improved treatment outcomes and reduced toxicity for patients by maximizing the target coverage and minimizing the radiation exposure of organs at risk.

Identifiants

pubmed: 37937259
doi: 10.1117/1.JMI.10.6.065501
pii: 23112GR
pmc: PMC10627232
doi:

Banques de données

figshare
['10.6084/m9.figshare.20140184']

Types de publication

Journal Article

Langues

eng

Pagination

065501

Subventions

Organisme : NCI NIH HHS
ID : T32 CA261856
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIDCR NIH HHS
ID : F31 DE029093
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE025248
Pays : United States
Organisme : NIBIB NIH HHS
ID : R25 EB025787
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218148
Pays : United States
Organisme : NIDCR NIH HHS
ID : F31 DE031502
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028290
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR003169
Pays : United States

Informations de copyright

© 2023 The Authors.

Références

Med Phys. 2021 Jul;48(7):e697-e732
pubmed: 33864283
Head Neck. 2004 Mar;26(3):241-6
pubmed: 14999799
Magn Reson Imaging. 2016 Jul;34(6):820-831
pubmed: 26969762
Phys Eng Sci Med. 2022 Jun;45(2):457-473
pubmed: 35235188
Clin Transl Radiat Oncol. 2017 Oct 10;7:13-19
pubmed: 29594224
J Med Imaging Radiat Oncol. 2014 Apr;58(2):237-43
pubmed: 24690247
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):199-217
pubmed: 29254773
Clin Transl Radiat Oncol. 2018 May 05;11:11-18
pubmed: 30014042
Radiologia (Engl Ed). 2019 May - Jun;61(3):191-203
pubmed: 30772004
AJR Am J Roentgenol. 1992 Feb;158(2):369-79
pubmed: 1729800
J Clin Oncol. 2010 Sep 20;28(27):4142-8
pubmed: 20697079
AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1283-7
pubmed: 16775280
Br J Radiol. 2018 May;91(1085):20170078
pubmed: 29436841
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):85-93
pubmed: 25015199
J Clin Oncol. 2006 Dec 20;24(36):5687-94
pubmed: 17179104
Radiographics. 1999 Mar-Apr;19(2):373-82
pubmed: 10194785
J Med Imaging Radiat Oncol. 2020 Feb;64(1):163-177
pubmed: 31646742
Radiother Oncol. 2021 Jul;160:185-191
pubmed: 33984348
AJNR Am J Neuroradiol. 2009 Jan;30(1):42-5
pubmed: 18653688
Semin Radiat Oncol. 2014 Jul;24(3):151-9
pubmed: 24931085
Radiat Oncol. 2010 Mar 15;5:21
pubmed: 20230613
IEEE Trans Image Process. 2018 Jan;27(1):206-219
pubmed: 29028191
Med Phys. 2020 Feb;47(2):626-642
pubmed: 31733164
Phys Med Biol. 2018 Feb 26;63(5):05TR01
pubmed: 29393071
Radiother Oncol. 2015 May;115(2):191-4
pubmed: 25866029
Radiology. 2015 Mar;274(3):752-63
pubmed: 25380454
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1606-1618
pubmed: 33340604
Pediatr Radiol. 2013 Mar;43(5):558-67
pubmed: 23224105
Skeletal Radiol. 2019 Dec;48(12):1905-1914
pubmed: 31154494
Cancers (Basel). 2021 Oct 28;13(21):
pubmed: 34771567
Strahlenther Onkol. 2021 Dec;197(12):1093-1103
pubmed: 33891126
Front Oncol. 2017 Apr 03;7:59
pubmed: 28421162
Phys Med Biol. 2021 Oct 13;66(20):
pubmed: 34243173
Cancers (Basel). 2022 Apr 10;14(8):
pubmed: 35454816
AJNR Am J Neuroradiol. 2018 Feb;39(2):362-368
pubmed: 29242364
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Acta Oncol. 2016 Nov;55(11):1305-1312
pubmed: 27607138
IEEE Trans Med Imaging. 1991;10(1):47-52
pubmed: 18222799
Radiother Oncol. 2020 Dec;153:106-113
pubmed: 33017604
Radiother Oncol. 2017 Feb;122(2):229-235
pubmed: 27497803
Radiother Oncol. 2016 Apr;119(1):179-84
pubmed: 26975240
AJR Am J Roentgenol. 1994 Jul;163(1):173-8
pubmed: 8010208
Eur J Cancer. 2019 Nov;122:42-52
pubmed: 31614288
J Appl Clin Med Phys. 2020 Jul;21(7):160-172
pubmed: 32432405
Radiat Oncol. 2017 Jan 26;12(1):28
pubmed: 28126030
Radiographics. 2014 Jan-Feb;34(1):217-33
pubmed: 24428292
Int J Radiat Oncol Biol Phys. 2022 Jun 1;113(2):426-436
pubmed: 35124134
AJNR Am J Neuroradiol. 2004 Jun-Jul;25(6):1092-8
pubmed: 15205156
J Magn Reson Imaging. 2008 Sep;28(3):543-58
pubmed: 18777528
Front Oncol. 2021 Mar 19;11:616156
pubmed: 33816247
Biosensors (Basel). 2022 Oct 20;12(10):
pubmed: 36291038
Radiother Oncol. 2019 Mar;132:114-120
pubmed: 30825959
Magn Reson Med. 2016 Feb;75(2):718-28
pubmed: 25772334
CA Cancer J Clin. 2022 Jan;72(1):34-56
pubmed: 34792808
J Appl Clin Med Phys. 2021 Aug;22(8):45-59
pubmed: 34275176
Cancer Imaging. 2016 Aug 03;16(1):20
pubmed: 27487932
Radiother Oncol. 2018 Jan;126(1):107-115
pubmed: 29100700
Radiother Oncol. 2008 Jan;86(1):25-9
pubmed: 18023488
AJR Am J Roentgenol. 2012 Jan;198(1):11-8
pubmed: 22194474
Invest Radiol. 1974 Nov-Dec;9(6):479-86
pubmed: 4430588
J Magn Reson Imaging. 2008 Jun;27(6):1448-54
pubmed: 18504735
J Magn Reson Imaging. 2004 Dec;20(6):1025-9
pubmed: 15558561

Auteurs

Travis C Salzillo (TC)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

M Alex Dresner (MA)

Philips Healthcare, Cleveland, Ohio, United States.

Ashley Way (A)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Kareem A Wahid (KA)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Brigid A McDonald (BA)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Sam Mulder (S)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Mohamed A Naser (MA)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Renjie He (R)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Yao Ding (Y)

MD Anderson Cancer Center, Radiation Physics, Houston, Texas, United States.

Alison Yoder (A)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Sara Ahmed (S)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Kelsey L Corrigan (KL)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Gohar S Manzar (GS)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Lauren Andring (L)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Chelsea Pinnix (C)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

R Jason Stafford (RJ)

MD Anderson Cancer Center, Imaging Physics, Houston, Texas, United States.

Abdallah S R Mohamed (ASR)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

John Christodouleas (J)

Elekta AB, Stockholm, Sweden.

Jihong Wang (J)

MD Anderson Cancer Center, Radiation Physics, Houston, Texas, United States.

Clifton David Fuller (CD)

MD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.

Classifications MeSH